Recurrent Pneumonia: A Review with Focus on Clinical Epidemiology and Modifiable Risk Factors in Elderly Patients

Drugs and Aging

Volumn 32, Issue 1, 2015, Pages 13-19

  Dang, T T ^a   Majumdar, S R ^a   Marrie, T J ^b   Eurich, D T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; PROTON PUMP INHIBITOR;

AGED; ASPIRATION; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DYSPHAGIA; FUNCTIONAL STATUS; HEART FAILURE; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN DEFICIENCY; LIFESTYLE; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; NORTH AMERICA; PHYSICIAN; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); COMMUNITY-ACQUIRED INFECTIONS; COMPLICATION;

ADRENAL CORTEX HORMONES; AGED; COMMUNITY-ACQUIRED INFECTIONS; HOSPITALIZATION; HUMANS; PNEUMONIA; PROTON PUMP INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE; RISK FACTORS;

EID: 84925519744     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-014-0229-6     Document Type: Review

References (65)

1. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20(4):820–37.
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Supplement 2):S27–72.
3. Torres A, Peetermans WE, Viegi G, et al. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68(11):1057–65.
4. Marrie TJ, Huang JQ. Epidemiology of community-acquired pneumonia in Edmonton, Alberta: an emergency department-based study. Can Respir J. 2005;12(3):139–42.
5. Marrie TJ, Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest. 2005;127(4):1260–70.
6. Johnstone J, Marrie TJ, Eurich DT, et al. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med. 2007;167(18):1938–43.
7. Winterbauer RH, Bedon GA, Ball JWC. Recurrent pneumonia predisposing illness and clinical patterns in 158 patients. Ann Intern Med. 1969;70(4):689–700.
8. Ekdahl K, Braconier JH, Rollof J. Recurrent pneumonia: a review of 90 adult patients. Scand J Infect Dis. 1992;24(1):71–6.
9. Garcia-Vidal C, Carratala J, Fernandez-Sabe N, et al. Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clin Microbiol Infect. 2009;15(11):1033–8.
10. Dang T, Eurich D, Weir D, et al. Rates and risk factors for recurrent pneumonia in patients hospitalized with community-acquired pneumonia: population-based prospective cohort study with 5 years of follow-up. Clin Infect Dis. 2014: 74–80.
11. El Solh AA, Brewer T, Okada M, et al. Indicators of recurrent hospitalization for pneumonia in the elderly. J Am Geriatr Soc. 2004;52(12):2010–5.
12. Hedlund J, Kalin M, Örtqvist Å. Recurrence of pneumonia in middle-aged and elderly adults after hospital-treated pneumonia: aetiology and predisposing conditions. Scand J Infect Dis. 1997;29(4):387–92.
13. Muder RR, Brennen C, Swenson DL, et al. Pneumonia in a long-term care facility: a prospective study of outcome. Arch Intern Med. 1996;156(20):2365–70.
14. Inoue Y, Koizumi A, Wada Y, et al. Risk and protective factors related to mortality from pneumonia among middleaged and elderly community residents: the JACC Study. J Epidemiol. 2007;17(6):194–202.
15. Baik I, Curhan GC, Rimm EB, et al. A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in us men and women. Arch Intern Med. 2000;160(20):3082–8.
16. Riquelme R, Torres A, El-Ebiary M, et al. Community-acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med. 1996;154(5):1450–5.
17. Yoshikawa TT, Marrie TJ. Community-acquired pneumonia in the elderly. Clin Infect Dis. 2000;31(4):1066–78.
18. Torres OH, Muñoz J, Ruiz D, et al. Outcome predictors of pneumonia in elderly patients: importance of functional assessment. J Am Geriatr Soc. 2004;52(10):1603–9.
19. Zalacain R, Torres A, Celis R, et al. Community-acquired pneumonia in the elderly: spanish multicentre study. Eur Respir J. 2003;21(2):294–302.
20. Lange P, Vestbo J, Nyboe J. Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. Eur Respir J. 1995;8(10):1694–8.
21. Almirall J, Bolibar I, Serra-Prat M, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J. 2008;31(6):1274–84.
22. Cunha B. Pneumonia in the elderly. Clin Microbiol Infect. 2001;7(11):581–8.
23. Almirall J, Bolíbar I, Balanzó X, et al. Risk factors for community-acquired pneumonia in adults: a population-based case–control study. Eur Respir J. 1999;13(2):349–55.
24. Vinogradova Y, Hippisley-Cox J, Coupland C. Identification of new risk factors for pneumonia: population-based case-control study. Br J Gen Pract. 2009;59(567):e329–38.
25. Farr BM, Bartlett CLR, Wadsworth J, et al. Risk factors for community-acquired pneumonia diagnosed upon hospital admission. Respir Med. 2000;94(10):954–63.
26. Marik PE, Kaplan D. Aspiration pneumonia and dysphagia in the elderly. Chest J. 2003;124(1):328–36.
27. Almirall J, Rofes L, Serra-Prat M, et al. Oropharyngeal dysphagia is a risk factor for community-acquired pneumonia in the elderly. Eur Respir J. 2013;41(4):923–8.
28. Janssens J-P. Pneumonia in the elderly (geriatric) population. Curr Opin Pulm Med. 2005;11(3):226–30.
29. Sjögren P, Nilsson E, Forsell M, et al. A systematic review of the preventive effect of oral hygiene on pneumonia and respiratory tract infection in elderly people in hospitals and nursing homes: effect estimates and methodological quality of randomized controlled trials. J Am Geriatr Soc. 2008;56(11):2124–30.
30. Ekdahl K, Braconier JH, Svanborg C. Immunoglobulin deficiencies and impaired immune response to polysaccharide antigens in adult patients with recurrent community-acquired pneumonia. Scand J Infect Dis. 1997;29(4):401–7.
31. Dahabreh IJ, Kent DM. Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA. 2011;305(8):822–3.
32. van Hylckama Vlieg A, Christiansen S, Luddington R, et al. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol. 2007;138(6):769–74.
33. Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006;368(9536):666–78.
34. Niimi A, Matsumoto H, Ueda T, et al. Impaired cough reflex in patients with recurrent pneumonia. Thorax. 2003;58(2):152–3.
35. Arai T, Sekizawa K, Ohrui T, et al. ACE inhibitors and protection against pneumonia in elderly patients with stroke. Neurology. 2005;64(3):573–4.
36. Myles PR, Hubbard RB, McKeever TM, et al. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case–control study. Pharmacoepidemiol Drug Saf. 2009;18(4):269–75.
37. Mortensen EM, Nakashima B, Cornell J, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis. 2012;55(11):1466–73.
38. Mukamal KJ, Ghimire S, Pandey R, et al. Antihypertensive medications and risk of community-acquired pneumonia. J Hypertens. 2010;28(2):401–5.
39. Van de Garde E, Souverein P, van den Bosch J, et al. Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population. Eur Respir J. 2006;27(6):1217–22.
40. Rafailidis PI, Matthaiou DK, Varbobitis I, et al. Use of ACE inhibitors and risk of community-acquired pneumonia: a review. Eur J Clin Pharmacol. 2008;64(6):565–73.
41. Ohkubo T, Chapman N, Neal B, et al. Effects of an angiotensin-converting enzyme inhibitor–based regimen on pneumonia risk. Am J Respir Crit Care Med. 2004;169(9):1041–5.
42. Dublin S, Jackson ML, Nelson JC, et al. Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ. 2009: 338–46.
43. Chalmers JD, Singanayagam A, Murray MP, et al. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med. 2008;121(11):1002–1007. e1.
44. Majumdar SR, McAlister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ. 2006;333(7576):999–1003.
45. Thomsen RW, Riis A, Kornum JB, et al. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med. 2008;168(19):2081–7.
46. Chopra V, Rogers MA, Buist M, et al. Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am J Med. 2012;125(11):1111–23.
47. Mortensen EM, Restrepo MI, Anzueto A, et al. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res. 2005;6(1):1617–24.
48. Chalmers JD, Short PM, Mandal P, et al. Statins in community acquired pneumonia: evidence from experimental and clinical studies. Respir Med. 2010;104(8):1081–91.
49. Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med. 2006;32(1):160–4.
50. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004;110(7):880–5.
51. Papazian L, Roch A, Charles P-E, et al. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. JAMA. 2013;310(16):1692–700.
52. Eurich DT, Sadowski CA, Simpson SH, et al. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med. 2010;123(1):47–53.
53. Gau JT, Acharya U, Khan S, et al. Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr. 2010;10:45–52.
54. Eom C-S, Jeon CY, Lim J-W, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. Can Med Assoc J. 2011;183(3):310–9.
55. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31(11):1165–77.
56. Eurich DT, Lee C, Marrie TJ, et al. Inhaled Corticosteroids and Risk of Recurrent Pneumonia: Population Based Nested Case Control Study. Clin Infect Dis. 2013: 1138–44.
57. Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med. 1994;96(4):313–20.
58. Molinos L, Clemente MG, Miranda B, et al. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect. 2009;58(6):417–24.
59. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169(3):219–29.
60. Gutiérrez F, Masiá M, Mirete C, et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect. 2006;53(3):166–74.
61. Kaplan V, Angus DC, Griffin MF, et al. Hospitalized community-acquired pneumonia in the elderly: age-and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med. 2002;165(6):766–72.
62. Ochoa-Gondar O, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis. 2014: 909–17.
63. Watson L, et al. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine. 2002;20(17):2166–73.
64. Örtqvist Å, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet. 1998;351(9100):399–403.
65. Johnstone J, et al. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin Infect Dis. 2010;51(1):15–22.